Archives: Agenda

• The impact of China’s biotech boom on global trials
• How do the global policies and regulatory difference impact the decision of China biotech
• The opportunities and challenges for clinical trials overseas and license out.

Moderator:

Xiaoyu Deng, Founder & CEO, MDCE

• 中国生物科技热潮对全球试验的影响
• 全球出海政策及监管差异对中国企业选择的决定影响
• License-out 与海外临床试验的不同机遇与挑战

主持嘉宾:

邓晓宇，创始人，希毅医学

• Updates on China’s National Medical Products Administration (NMPA) regulations
• Recent reforms in drug and device approval processes
• Best practices for obtaining IND and NDA approvals in China

• 中国国家药品监督管理局（NMPA）法规更新
• 药品和医疗器械审批流程的最新改革
• 在中国获得IND（新药临床试验申请）和NDA（新药上市申请）批准的最佳实践